Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2018 /
Long term data from JULIET trial, using tisagenlecleucel for patients with relapsed or treatment-resistant DLBCL

1st - 4th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 131

Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, USA

Dr Richard Maziarz speaks to ecancer at ASH 2018 about follow-up results from the JULIET trial for patients with relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL).

He reports that 18 months after treatment with product tisagenlecleucel, patients with relapsed or treatment-resistant diffuse large B-cell lymphoma continue to show a high response rates.

Dr Richard Maziarz also explains the adverse effects of the treatment, as well as the potential implications - which he describes as changing the natural history of the disease.

What his press conference here.

Read the article here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content. 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation